GLAXOSMITHKLINE - The Daily Mail's market report cites "industry gossip" that Glaxo is lining up a $55 per share bid for U.S. firm Theravance , in which it already has a stake
Sentiment: Strong Buy
Too bad my option expiring today :-(
Turn out to be just rumor .... Not much change in price . Rumor is just rumor
More than a rumour, GSK has not formally sent take over documents , maybe your timing is off but this is more than a rumour it will get done, too much money for Glaxo in the revenue streams...
THRX is indeed worth $50 plus.. GSK will be wise to "take it ova".. Good luck to all THRX longs
Yes they will the deal would be accretive for GSK and they won't let THRX do another deal, they wanted to wait til year end but now will pursue Theravance aggressively. The revenue streams are so large that the deal makes perfect sense for Glaxo....